InvestorsHub Logo

Stockpennies

04/17/20 10:10 AM

#69162 RE: fsoalex #69160

statement from Giliad after pump story.... were still #1 IMO



"We understand the urgent need for a Covid-19 treatment and the resulting interest in data on our investigational antiviral drug remdesivir. The totality of the data need to be analysed in order to draw any conclusions from the trial."

"Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19. We expect the data from our Phase 3 study in patients with severe Covid-19 infection to be available at the end of this month, and additional data from other studies to become available in May."